A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
RACOON SAGA: Interdisciplinary Research for Better Therapy Decisions in Sarcoma Treatment
Sarcomas are rare tumors that pose particular challenges to both medicine and research. Their heterogeneity makes precise diagnostics difficult, which…
Lung Cancer Screening in Germany – A Turning Point for Early Detection
Few topics are currently as impactful in radiology as lung cancer screening. From 2026, Germany is expected to roll out a nationwide program, marking…
Leave No Data Behind: Commitment to Data Excellence
At Mint Medical, we understand data as a cornerstone for improving patient care and groundbreaking research. Our mission is clear: Leave No Data…